Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-TRANS fentanyl + naltrexone
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
D-TRANS fentanyl + naltrexone is an abuse-deterrent transdermal drug delivery system developed by ALZA Corporation (a subsidiary of Johnson & Johnson) for the management of chronic pain in opioid-tolerant patients. The system utilizes ALZA's proprietary D-TRANS technology to deliver fentanyl, a potent mu-opioid receptor agonist, while sequestering naltrexone, a mu-opioid receptor antagonist. The patch is designed so that naltrexone does not significantly permeate intact skin, allowing the therapeutic delivery of fentanyl for analgesia. However, if the patch is tampered with—such as through extraction for oral or intravenous use—the naltrexone is released to antagonize the opioid effects of fentanyl, thereby deterring misuse and abuse. Clinical development reached at least Phase 2 safety evaluations comparing the system to standard fentanyl patches like Duragesic.
- Brand names
- D-TRANS
- Other names
- fentanyl + naltrexone transdermal systemD-TRANS fentanyl with naltrexone
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on D-TRANS fentanyl + naltrexone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-TRANS fentanyl + naltrexone.